Symbols / MTNB Stock $0.56 -4.41% Matinas BioPharma Holdings, Inc.

Healthcare • Biotechnology • United States • ASE
MTNB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jerome D. Jabbour J.D.
Exch · Country ASE · United States
Market Cap 3.61M
Enterprise Value 1.44M
Income -10.96M
Sales —
FCF (ttm) -3.34M
Book/sh 0.75
Cash/sh 0.62
Employees 2
Insider 10d —
IPO Jul 21, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.19
PEG —
P/S —
P/B 0.75
P/C —
EV/EBITDA -0.21
EV/Sales —
Quick Ratio 2.73
Current Ratio 2.79
Debt/Eq 28.03
LT Debt/Eq —
EPS (ttm) -2.00
EPS next Y -3.00
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-08-13
Earnings (prior) 2025-08-13
ROA -43.83%
ROE -166.59%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 6.41M
Shs Float 5.23M
Insider Own 22.11%
Instit Own 7.04%
Short Float 0.05%
Short Ratio 0.12
Short Interest 3.51K
52W High 3.09
vs 52W High -81.75%
52W Low 0.48
vs 52W Low 17.50%
Beta 1.62
Impl. Vol. —
Rel Volume 1.34
Avg Volume 26.57K
Volume 35.50K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.59
Price $0.56
Change -4.41%
About

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.56
Latest analyst target
3. DCF / Fair value
$-9.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.56
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-31 down Maxim Group Buy → Hold —
2023-01-31 reit HC Wainwright & Co. — → Buy $3
2020-08-13 main Aegis Capital — → Buy $4
2020-01-27 init Piper Sandler — → Overweight $3
2020-01-24 init SunTrust Robinson Humphrey — → Buy $3
2019-06-26 init HC Wainwright & Co. — → Buy $4
2019-05-17 init BTIG — → Buy $5
2019-02-11 init Roth Capital — → Buy —
2018-11-13 main Maxim Group Buy → Buy $5
2018-08-13 main Maxim Group Buy → Buy $2
2018-07-10 main Maxim Group Buy → Buy $3
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
1.10
-65.62%
3.19
Operating Revenue
0.00
0.00
-100.00%
1.10
-65.62%
3.19
Operating Expense
6.96
-65.48%
20.16
-18.90%
24.86
-10.50%
27.78
Research And Development
0.09
-99.26%
11.43
-21.09%
14.49
-13.13%
16.68
Selling General And Administration
6.88
-21.24%
8.73
-15.85%
10.37
-6.55%
11.10
General And Administrative Expense
6.88
-21.24%
8.73
-15.85%
10.37
-6.55%
11.10
Other Gand A
6.88
-21.24%
8.73
-15.85%
10.37
-6.55%
11.10
Total Expenses
6.96
-65.48%
20.16
-18.90%
24.86
-10.50%
27.78
Operating Income
-6.96
+65.48%
-20.16
+15.16%
-23.77
+3.35%
-24.59
Total Operating Income As Reported
-6.96
+71.70%
-24.59
-3.48%
-23.77
+3.35%
-24.59
EBITDA
-6.50
+66.11%
-19.19
+15.93%
-22.82
+3.66%
-23.69
Normalized EBITDA
-3.38
+77.10%
-14.76
+36.68%
-23.31
+14.25%
-27.18
Reconciled Depreciation
0.46
-53.09%
0.97
+3.29%
0.94
+4.79%
0.90
EBIT
-6.96
+65.48%
-20.16
+15.16%
-23.77
+3.35%
-24.59
Total Unusual Items
-3.12
+29.50%
-4.43
-1015.50%
0.48
-86.14%
3.49
Total Unusual Items Excluding Goodwill
-3.12
+29.50%
-4.43
-1015.50%
0.48
-86.14%
3.49
Special Income Charges
0.04
+100.84%
-4.43
-1015.50%
0.48
-86.14%
3.49
Impairment Of Capital Assets
0.00
-100.00%
4.43
0.00
—
Net Income
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Pretax Income
-10.35
+57.48%
-24.33
-6.05%
-22.94
-9.26%
-21.00
Other Income Expense
-3.38
+18.81%
-4.17
-605.95%
0.82
-77.07%
3.59
Other Non Operating Income Expenses
-0.26
-199.62%
0.26
-22.94%
0.34
+233.33%
0.10
Gain On Sale Of Security
-3.16
—
—
—
Gain On Sale Of Business
—
0.00
-100.00%
0.48
-86.14%
3.49
Tax Provision
0.00
+100.00%
-0.08
0.00
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.01
0.00
0.00
Net Income Including Noncontrolling Interests
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Net Income From Continuing Operation Net Minority Interest
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Net Income From Continuing And Discontinued Operation
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Net Income Continuous Operations
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Normalized Income
-7.22
+63.59%
-19.83
+15.33%
-23.43
+4.34%
-24.49
Net Income Common Stockholders
-10.96
+54.79%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Otherunder Preferred Stock Dividend
0.62
0.00
—
—
Diluted EPS
—
-4.98
+5.68%
-5.28
-5.60%
-5.00
Basic EPS
—
-4.98
+5.68%
-5.28
-5.60%
-5.00
Basic Average Shares
—
4.87
+11.98%
4.35
+0.21%
4.34
Diluted Average Shares
—
4.87
+11.98%
4.35
+0.21%
4.34
Diluted NI Availto Com Stockholders
-10.96
+54.79%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Gain On Sale Of PPE
0.04
0.00
—
—
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
25.10
Current Assets
15.54
Cash Cash Equivalents And Short Term Investments
13.76
Cash And Cash Equivalents
4.79
Other Short Term Investments
8.97
Prepaid Assets
—
Restricted Cash
0.05
Other Current Assets
1.74
Total Non Current Assets
9.56
Net PPE
5.01
Gross PPE
6.70
Accumulated Depreciation
-1.70
Properties
0.00
Other Properties
5.55
Leases
1.16
Goodwill And Other Intangible Assets
4.35
Goodwill
1.34
Other Intangible Assets
3.02
Other Non Current Assets
0.20
Total Liabilities Net Minority Interest
5.86
Current Liabilities
2.62
Payables And Accrued Expenses
1.96
Payables
0.51
Accounts Payable
0.51
Current Accrued Expenses
1.45
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
0.66
Current Capital Lease Obligation
0.66
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
0.27
Total Non Current Liabilities Net Minority Interest
3.24
Long Term Debt And Capital Lease Obligation
2.90
Long Term Capital Lease Obligation
2.90
Non Current Deferred Liabilities
0.34
Non Current Deferred Taxes Liabilities
0.34
Stockholders Equity
19.25
Common Stock Equity
19.25
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
—
Share Issued
4.35
Ordinary Shares Number
4.35
Treasury Shares Number
0.00
Additional Paid In Capital
195.04
Retained Earnings
-175.57
Gains Losses Not Affecting Retained Earnings
-0.22
Other Equity Adjustments
-0.22
Total Equity Gross Minority Interest
19.25
Total Capitalization
19.25
Working Capital
12.92
Invested Capital
19.25
Total Debt
3.56
Capital Lease Obligations
3.56
Net Tangible Assets
14.89
Tangible Book Value
14.89
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-7.01
+55.86%
-15.88
-3.97%
-15.28
+20.24%
-19.16
Cash Flow From Continuing Operating Activities
-7.01
+55.86%
-15.88
-3.97%
-15.28
+20.24%
-19.16
Net Income From Continuing Operations
-10.35
+57.34%
-24.25
-5.71%
-22.94
-9.26%
-21.00
Depreciation Amortization Depletion
0.46
-53.09%
0.97
+3.29%
0.94
+4.79%
0.90
Depreciation
0.46
-53.09%
0.97
+3.29%
0.94
+4.79%
0.90
Depreciation And Amortization
0.46
-53.09%
0.97
+3.29%
0.94
+4.79%
0.90
Other Non Cash Items
—
-0.02
-115.89%
0.11
-78.69%
0.50
Stock Based Compensation
1.02
-67.98%
3.19
-35.43%
4.95
-5.36%
5.23
Asset Impairment Charge
0.00
-100.00%
4.43
0.00
—
Deferred Tax
0.00
+100.00%
-0.08
0.00
—
Deferred Income Tax
0.00
+100.00%
-0.08
0.00
—
Operating Gains Losses
3.37
—
0.00
-50.00%
0.00
Gain Loss On Investment Securities
3.16
—
—
—
Gain Loss On Sale Of PPE
0.24
0.00
-100.00%
0.00
-50.00%
0.00
Change In Working Capital
-1.51
-1052.67%
-0.13
-107.86%
1.67
+134.81%
-4.79
Change In Prepaid Assets
0.67
+13.29%
0.59
-85.26%
3.98
+194.90%
-4.20
Change In Payables And Accrued Expense
-1.13
-1698.41%
-0.06
+96.41%
-1.75
-2336.11%
-0.07
Change In Accrued Expense
-1.35
-480.06%
0.36
+121.56%
-1.65
-763.05%
0.25
Change In Payable
0.22
+152.51%
-0.42
-306.80%
-0.10
+67.91%
-0.32
Change In Account Payable
0.22
+152.51%
-0.42
-306.80%
-0.10
+67.91%
-0.32
Change In Other Current Liabilities
-1.04
-59.08%
-0.66
-16.55%
-0.56
-8.08%
-0.52
Investing Cash Flow
0.34
-96.36%
9.21
-30.46%
13.24
+171.52%
4.88
Cash Flow From Continuing Investing Activities
0.34
-96.36%
9.21
-30.46%
13.24
+171.52%
4.88
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.22
+75.56%
-0.89
Purchase Of PPE
—
0.00
+100.00%
-0.22
+75.56%
-0.89
Capital Expenditure
—
—
-0.22
+75.56%
-0.89
Net Investment Purchase And Sale
0.00
-100.00%
9.21
-31.59%
13.46
+133.32%
5.77
Purchase Of Investment
0.00
+100.00%
-8.44
0.00
+100.00%
-9.48
Sale Of Investment
0.00
-100.00%
17.64
+31.09%
13.46
-11.74%
15.25
Net Other Investing Changes
0.34
—
—
—
Financing Cash Flow
3.39
-63.04%
9.17
+131157.14%
-0.01
-108.86%
0.08
Cash Flow From Continuing Financing Activities
3.39
-63.04%
9.17
+131157.14%
-0.01
-108.86%
0.08
Net Issuance Payments Of Debt
-0.01
-80.00%
-0.01
+28.57%
-0.01
+65.00%
-0.02
Repayment Of Debt
-0.01
-80.00%
-0.01
+28.57%
-0.01
+65.00%
-0.02
Long Term Debt Payments
-0.01
-80.00%
-0.01
+28.57%
-0.01
+65.00%
-0.02
Net Long Term Debt Issuance
-0.01
-80.00%
-0.01
+28.57%
-0.01
+65.00%
-0.02
Net Common Stock Issuance
0.00
-100.00%
9.18
0.00
0.00
Proceeds From Stock Option Exercised
0.13
0.00
0.00
-100.00%
0.10
Net Other Financing Charges
-0.03
—
—
—
Changes In Cash
-3.29
-231.56%
2.50
+222.22%
-2.04
+85.61%
-14.20
Beginning Cash Position
7.53
+49.57%
5.04
-28.86%
7.08
-66.73%
21.28
End Cash Position
4.25
-43.60%
7.53
+49.57%
5.04
-28.86%
7.08
Free Cash Flow
-7.01
+55.86%
-15.88
-2.51%
-15.50
+22.71%
-20.05
Common Stock Issuance
0.00
-100.00%
9.18
0.00
0.00
Issuance Of Capital Stock
3.30
-64.05%
9.18
0.00
0.00
Net Preferred Stock Issuance
3.30
0.00
—
—
Preferred Stock Issuance
3.30
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category